Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Cassiopea S.p.A.
  6. News
  7. Summary
    SKIN   IT0005108359

CASSIOPEA S.P.A.

(SKIN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Cassiopea S p A : Concludes License, Supply Deal for Acne Drug Winlevi

08/31/2021 | 02:16am EDT


© MT Newswires 2021
All news about CASSIOPEA S.P.A.
10/04COSMO PHARMACEUTICALS N : Initiates Public Exchange Offer For Cassiopea
MT
10/04CASSIOPEA S P A : Cosmo pharmaceuticals n.v. launches public exchange offer to acquire cas..
EQ
10/04Cosmo pharmaceuticals n.v. launches -2-
DJ
10/04Cosmo pharmaceuticals n.v. launches public exchange offer to acquire cassiopea s.p.a.
DJ
10/04Cosmo Pharmaceuticals Intends to Acquire Cassiopea
CI
10/04Cosmo Pharmaceuticals N.V. made an offer to acquire remaining 53.4% stake in Cassiopea ..
CI
09/13CASSIOPEA S P A : Public Investor Presentation H.C. Wainwright Annual Global Conference
PU
09/10CASSIOPEA S P A : Female Androgenetic Alopecia Treatment Shows Improvement in Mid-Stage Tr..
MT
09/10EQS-ADHOC : Cassiopea SpA Announces Topline Results of Phase II Proof of Concept Trial of ..
DJ
09/10Cassiopea SpA Announces Topline Results of Phase II Proof of Concept Trial of Clascoter..
CI
More news
Financials
Sales 2021 38,8 M 45,1 M 45,1 M
Net income 2021 25,0 M 29,1 M 29,1 M
Net cash 2021 29,7 M 34,5 M 34,5 M
P/E ratio 2021 13,0x
Yield 2021 -
Capitalization 330 M 384 M 384 M
EV / Sales 2021 7,74x
EV / Sales 2022 18,3x
Nbr of Employees 11
Free-Float 41,2%
Chart CASSIOPEA S.P.A.
Duration : Period :
Cassiopea S.p.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CASSIOPEA S.P.A.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 30,71 €
Average target price 47,94 €
Spread / Average Target 56,1%
EPS Revisions
Managers and Directors
Diana Harbort Chief Executive Officer & Executive Director
Pierpaolo Guzzo Chairman & Chief Financial Officer
Luigi Moro Chief Scientific Officer
Alessandro Mazzetti Chief Medical Officer
Martina Cartwright Senior Director-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
CASSIOPEA S.P.A.-32.37%384
GILEAD SCIENCES, INC.14.98%83 830
BIONTECH SE251.28%65 071
WUXI APPTEC CO., LTD.25.77%64 894
REGENERON PHARMACEUTICALS17.86%58 504
VERTEX PHARMACEUTICALS-20.84%48 121